Panitumumab, a recombinant, fully humanized, immunoglobulin G2 (IgG2) monoclonal anti–epidermal growth factor receptor antibody is approved by the US Food and Drug Administration for selected metastatic colorectal cancer.1,2 We report a case of an immune-complex glomerulonephritis (GN) developed in close temporal association with panitumumab treatment.